Spironolactone Versus Placebo in Maintenance Dialysis Patients: Insights from the ACHIEVE Trial and Contemporary Evidence
Posted inClinical Updates Nephrology Specialties

Spironolactone Versus Placebo in Maintenance Dialysis Patients: Insights from the ACHIEVE Trial and Contemporary Evidence

This review consolidates evidence from the ACHIEVE trial and related studies evaluating spironolactone's efficacy and safety in patients undergoing maintenance dialysis, highlighting lack of cardiovascular benefit and discussing future directions for mineralocorticoid receptor antagonism in this population.
Emerging APRIL-Targeted Therapies in IgA Nephropathy and IgA Vasculitis Nephritis: Clinical Advances with Zigakibart, Sibeprenlimab, and Telitacicept
Posted inAllergy & Immunology Clinical Updates Nephrology Specialties

Emerging APRIL-Targeted Therapies in IgA Nephropathy and IgA Vasculitis Nephritis: Clinical Advances with Zigakibart, Sibeprenlimab, and Telitacicept

Recent clinical trials of APRIL-targeted monoclonal antibodies—zigakibart, sibeprenlimab, and telitacicept—demonstrate safety and significant proteinuria reduction in IgA nephropathy and IgA vasculitis nephritis, offering promising disease-modifying therapeutic options.
Complementary and Alternative Medicine Usage in Chronic Kidney Disease: Prevalence, Patterns, and Clinical Implications
Posted inNephrology Specialties

Complementary and Alternative Medicine Usage in Chronic Kidney Disease: Prevalence, Patterns, and Clinical Implications

Complementary and alternative medicine (CAM) use is prevalent in chronic kidney disease (CKD), with 43% of patients globally employing CAM modalities. Nutritional supplements, mind-body practices, and traditional medicines are widely used, yet non-disclosure to healthcare providers is common, underscoring the need for open clinical communication.